1. Home
  2. LCTX vs JSPR Comparison

LCTX vs JSPR Comparison

Compare LCTX & JSPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LCTX
  • JSPR
  • Stock Information
  • Founded
  • LCTX 1990
  • JSPR 2018
  • Country
  • LCTX United States
  • JSPR United States
  • Employees
  • LCTX N/A
  • JSPR N/A
  • Industry
  • LCTX Biotechnology: Biological Products (No Diagnostic Substances)
  • JSPR Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • LCTX Health Care
  • JSPR Health Care
  • Exchange
  • LCTX Nasdaq
  • JSPR Nasdaq
  • Market Cap
  • LCTX 95.2M
  • JSPR 85.8M
  • IPO Year
  • LCTX N/A
  • JSPR N/A
  • Fundamental
  • Price
  • LCTX $0.49
  • JSPR $4.73
  • Analyst Decision
  • LCTX Strong Buy
  • JSPR Strong Buy
  • Analyst Count
  • LCTX 5
  • JSPR 10
  • Target Price
  • LCTX $4.20
  • JSPR $62.50
  • AVG Volume (30 Days)
  • LCTX 1.3M
  • JSPR 178.9K
  • Earning Date
  • LCTX 05-08-2025
  • JSPR 05-13-2025
  • Dividend Yield
  • LCTX N/A
  • JSPR N/A
  • EPS Growth
  • LCTX N/A
  • JSPR N/A
  • EPS
  • LCTX N/A
  • JSPR N/A
  • Revenue
  • LCTX $9,499,000.00
  • JSPR N/A
  • Revenue This Year
  • LCTX N/A
  • JSPR N/A
  • Revenue Next Year
  • LCTX $232.66
  • JSPR N/A
  • P/E Ratio
  • LCTX N/A
  • JSPR N/A
  • Revenue Growth
  • LCTX 6.19
  • JSPR N/A
  • 52 Week Low
  • LCTX $0.37
  • JSPR $3.13
  • 52 Week High
  • LCTX $1.40
  • JSPR $26.84
  • Technical
  • Relative Strength Index (RSI)
  • LCTX 54.53
  • JSPR 53.34
  • Support Level
  • LCTX $0.37
  • JSPR $3.87
  • Resistance Level
  • LCTX $0.44
  • JSPR $4.99
  • Average True Range (ATR)
  • LCTX 0.04
  • JSPR 0.40
  • MACD
  • LCTX 0.01
  • JSPR 0.18
  • Stochastic Oscillator
  • LCTX 81.99
  • JSPR 86.02

About LCTX Lineage Cell Therapeutics Inc.

Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.

About JSPR Jasper Therapeutics Inc.

Jasper Therapeutics Inc is a clinical-stage biotechnology company dedicated to enabling cures through hematopoietic stem cell therapy. It is focused on the development and commercialization of safer and more effective conditioning agents and stem cell engineering to allow for expanded use of stem cell transplantation and ex vivo gene therapy.

Share on Social Networks: